Using semaglutide to help women with a history of gestational diabetes return to normal blood sugar levels

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of semaglutide 1mg (Ozempic®) in helping postpartum women who have experienced gestational diabetes mellitus (GDM) and currently have dysglycemia to achieve normoglycemia. The research focuses on women aged 18 to 45 who are between 6 months and 10 years postpartum and have specific glycemic impairments. Participants will be randomly assigned to receive either semaglutide or a placebo, with the goal of determining if the medication can effectively reverse dysglycemia and reduce the risk of developing type 2 diabetes in the future. The study aims to fill a critical gap in pharmacologic options for managing postpartum diabetes recovery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female
2. 18 - 45 years old (inclusive)
3. History of gestational diabetes in most recent pregnancy
4. 6 months - 10 years postpartum
5. BMI ≥ 25 kg/m2
6. Use of long-acting reversible contraception or bilateral tubal ligation
7. Dysglycemia as determined by glycemic response to 75g, 2-hour OGTT: either impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT):

   1. Fasting glucose 100-125mg/dL (inclusive) and/or
   2. 120 minute glucose 140-199mg/dL (inclusive)
8. Willingness to maintain physical activity level throughout study duration
9. Willingness to standardize diet for 3 days prior to OGTT
10. Ability to provide informed consent before any trial-related activities

Exclusion Criteria:

1. Body weight \> 350lb
2. Pregnant or the intention of becoming pregnant or not using adequate contraceptive measures.
3. Breastfeeding within 3 months of screening visit 1
4. Post-menopausal
5. Desiring pregnancy within study participation period or two months after participation ends (i.e. 10 months from enrolment)
6. Use of tobacco products within past 6 months
7. Substance or alcohol abuse
8. Presence of significant systemic disease including: diabetes mellitus (type 1 or type 2), cardiac disease (e.g. congestive heart failure), renal impairment (e.g. serum creatinine levels ≥ 1.4 mg/dL or eGFR \< 60), hepatic disease (including viral hepatitis, toxic hepatic damage, jaundice of unknown aetiology, or abnormal liver function tests), pancreatitis, uncontrolled thyroid disease (e.g. documented abnormal TSH), adrenal disease (including Cushing's syndrome, congenital adrenal hyperplasia), hyperlipidemia (fasting triglycerides \> 399mg%), untreated or poorly controlled hypertension (resting blood pressure \>159/94 mmHg)
9. History of or presence of: eating disorder, malignant disease requiring chemotherapy, or debilitating psychiatric disorder such as psychosis or neurological condition that could confound outcome variables
10. History of bariatric surgery
11. Use of medications for glucose regulation: insulin (e.g. Humalog, Novolog, Humulin), pramlintide, metiglinides, metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors within four weeks of screening visit 1
12. Use of medications for anti-obesity or weight loss within four weeks of screening visit 1
13. Use of medications known to exacerbate glucose dysfunction (such as isotretinoin or corticosteroids) within four weeks of screening visit 1
14. Known or suspected allergy to trial medication, excipients, or related products
15. Contraindications to study medications: patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
16. Current or recent past (within 3 months) participation in another experimental drug trial
17. Previous randomization in this trial
18. Receipt of any investigational drug within 6 months prior to this trial

Where it's running

• Woman's Hospital
  Baton Rouge, Louisiana, United States Recruiting

Study contacts

• Principal investigator: Elizabeth Sutton, PhD — Woman's Hospital, Louisiana
• Study coordinator: Briasha Jones, MPH
• Email: briasha.jones@womans.org
• Phone: 225-924-8446

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-Intensity Interval Training vs. Continuous Endurance Training in Prediabetes

  This study tests whether short bursts of intense exercise or steady, longer workouts can improve blood sugar control and fitness in people with prediabetes.

  Recruiting Riphah International University · Lahore, Punjab Province · NCT07713030

• 7-Ketolithocholic Acid for people with prediabetes

  This study tests whether 7-Ketolithocholic Acid, used with a low-sugar, reduced-calorie diet and more exercise, can lower fasting blood sugar in adults with prediabetes.

  Recruiting at 8 sites ICE S.p.A. · Bordighera and 7 other locations · NCT07650123

• Continuous glucose monitoring to help adults with prediabetes manage blood sugar

  This study will try wearing a continuous glucose monitor to help adults in Singapore with prediabetes change behaviors and manage blood sugar compared with usual health coaching.

  Recruiting at 2 sites SingHealth Polyclinics · Singapore and 1 other locations · NCT07371546

• Healthy beef-centric diet versus a Healthy U.S.-Style diet for adults with pre-diabetes or metabolic syndrome

  This 5-week randomized test will see if a beef-centered, low-carbohydrate diet reduces inflammation and improves metabolic health in adults with pre-diabetes or metabolic syndrome.

  Recruiting National Cattlemen's Beef Association, a contractor to the Beef Checkoff · Guelph, Ontario - on · NCT07269847

• EMR prompts in primary care to help prevent prediabetes from becoming diabetes

  This project will test whether electronic medical record prompts for doctors in primary care help adults with prediabetes avoid developing diabetes.

  Recruiting National University Polyclinics, Singapore · Singapore · NCT07252700

• Long-term effects of time-restricted eating on cardiometabolic health

  This 54-week study will test if limiting daily eating to an 8–12 hour window helps adults with metabolic syndrome and pre-diabetes improve blood sugar, cholesterol, blood pressure, and body composition.

  Recruiting Phase 2 University of California, San Diego · La Jolla, California · NCT07189234

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.